- Home
- EDRY vs CRIS Comparison
EDRY vs CRIS Comparison
Compare EDRY & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | CRIS |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 14.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | EDRY | CRIS |
|---|---|---|
| Price | $12.95 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 3.2K | ★ 115.6K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,384,447.00 | $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | $21.94 | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $7.60 | $1.02 |
| 52 Week High | $16.14 | $4.50 |
Technical Indicators
Market Signals| Indicator | EDRY | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 40.64 |
| Support Level | $12.94 | $1.14 |
| Resistance Level | $13.75 | $1.41 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 56.69 | 8.78 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.